Drug Utilisation and Cost Analysis in End-Stage Renal Disease Patients: A Prospective Observational Study

Open Access

Year : 2025 | Volume : 15 | Issue : 02 | Page : 1 12
    By

    R. Dileep,

  • B. Premkumar,

  • T. Farhana Thansi,

  • S. Gowtham,

  • A. K. Naveena,

  • S. Saranya,

  1. Researcher, Department of Pharmaceutics & Biotechnology, Sree Abirami College of Pharmacy, [Affiliated to The Tamil Nadu Dr. M. G. R. Medical University, Chennai], Eachanari, Coimbatore, Tamil Nadu, India
  2. Researcher, Department of Pharmaceutics & Biotechnology, Sree Abirami College of Pharmacy, [Affiliated to The Tamil Nadu Dr. M. G. R. Medical University, Chennai], Eachanari, Coimbatore, Tamil Nadu, India
  3. Researcher, Department of Pharmaceutics & Biotechnology, Sree Abirami College of Pharmacy, [Affiliated to The Tamil Nadu Dr. M. G. R. Medical University, Chennai], Eachanari, Coimbatore, Tamil Nadu, India
  4. Researcher, Department of Pharmaceutics & Biotechnology, Sree Abirami College of Pharmacy, [Affiliated to The Tamil Nadu Dr. M. G. R. Medical University, Chennai], Eachanari, Coimbatore, Tamil Nadu, India
  5. Researcher, Department of Pharmaceutics & Biotechnology, Sree Abirami College of Pharmacy, [Affiliated to The Tamil Nadu Dr. M. G. R. Medical University, Chennai], Eachanari, Coimbatore, Tamil Nadu, India
  6. Researcher, Department of Pharmaceutics & Biotechnology, Sree Abirami College of Pharmacy, [Affiliated to The Tamil Nadu Dr. M. G. R. Medical University, Chennai], Eachanari, Coimbatore, Tamil Nadu, India

Abstract

Chronic Kidney Disease (CKD) is a condition in which the kidneys are damaged and unable to efficiently remove waste and excess fluid from the blood. Dialysis serves as a treatment for CKD by artificially carrying out the kidney’s filtering functions. This prospective observational cross-sectional study was conducted to evaluate drug utilization patterns, economic burden, and health-related quality of life (HRQoL) among patients with end-stage renal disease (ESRD) undergoing dialysis. Over three months, 60 adults, all receiving haemodialysis for longer than three months, were joined from different centres. Data were gathered using a prepared questionnaire focused on sociodemographic background, prescribed medicines and cost issues. The Kidney Disease Quality of Life-36 (KDQOL-36) questionnaire was used to assess HRQoL, covering aspects such as physical and mental health, symptom burden, and the overall impact of kidney disease. Statistical analysis, including t-tests, ANOVA, and chi-square tests, was employed to explore associations between HRQoL scores and demographic variables. Most people in the study were male (65%) and fell between the ages of 41 and 60. The most frequent medications given to haemodialysis patients were antihypertensives, erythropoietin, diuretics and phosphate binders, suggesting many patients were on several medications at once. The average monthly cost of dialysis was found to be significant, with many patients depending on out-of-pocket expenditure, posing a substantial financial strain. The study concludes that ESRD patients on dialysis face complex drug regimens, high treatment costs, and compromised quality of life. These findings emphasize the importance of optimizing pharmacotherapy, implementing cost-effective healthcare strategies, and providing comprehensive psychosocial support to improve patient well-being and healthcare outcomes

Keywords: Statistical analysis, Erythropoietin, Kidney Disease Quality of Life, End-stage renal disease, chi-square tests

[This article belongs to Research and Reviews: A Journal of Health Professions ]

How to cite this article:
R. Dileep, B. Premkumar, T. Farhana Thansi, S. Gowtham, A. K. Naveena, S. Saranya. Drug Utilisation and Cost Analysis in End-Stage Renal Disease Patients: A Prospective Observational Study. Research and Reviews: A Journal of Health Professions. 2025; 15(02):1-12.
How to cite this URL:
R. Dileep, B. Premkumar, T. Farhana Thansi, S. Gowtham, A. K. Naveena, S. Saranya. Drug Utilisation and Cost Analysis in End-Stage Renal Disease Patients: A Prospective Observational Study. Research and Reviews: A Journal of Health Professions. 2025; 15(02):1-12. Available from: https://journals.stmjournals.com/rrjohp/article=2025/view=224969


References

  1. Fox CS, Matsushita K, Woodward M, Bilo HJG, Chalmers J, Heerspink HJL, et al. Associations of kidney disease measures with mortality and end-stage renal disease in individuals with and without diabetes: a meta-analysis. Lancet. 2012 Oct 27;380(9854):1662–73.
  2. Bello AK, Abu-Alfa AK, et al. An update on the global disparities in kidney disease burden and care across world countries and regions. Lancet Glob Health. 2024 Mar;12(3):382–95.
  3. World Kidney Day. Chronic Kidney Disease [Internet]. 2015 [cited 2025 Aug 2]. Available from: http://www.worldkidneyday.org/faqs/chronic-kidney-disease/
  4. Rovin BH, Parikh SV, Alarcón GS, et al. KDIGO 2024 Clinical Practice Guideline for the Management of Lupus Nephritis. Kidney Int. 2024 Jan;105(1):S1–S69.
  5. Sharma S, Sharma A, Tejpal S. The protective role of cinnamaldehyde in kidney injury: modulation of NF-κB and PI3K/Akt signaling pathways. J Sci Res Adv Biomed. 2025;4(1):132–41.
  6. El-Reshaid W, Abdul-Fattah H. Sonographic assessment of renal size in healthy adults. Med Princ Pract. 2014;23(5):432–6.
  7. McMahon RS, Penfold D, Bashir K. Anatomy, Abdomen and Pelvis: Kidney Collecting Ducts. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024 May 1.
  8. Madrazo-Ibarra A, Vaitla P. Histology, Nephron. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2023 Feb 17.
  9. Falkson SR, Bordoni B. Anatomy, Abdomen and Pelvis: Bowman Capsule. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2023 Aug 7.
  10. Pollak MR, Quaggin SE, Hoenig MP, Dworkin LD. The glomerulus: the sphere of influence. Clin J Am Soc Nephrol. 2014 Aug;9(8):1461–9.
  11. Muroya Y, He X, Fan L, Wang S, Xu R, Fan F, et al. Enhanced renal ischemia-reperfusion injury in aging and diabetes. Am J Physiol Renal Physiol. 2018 Dec;315(6):F1843–54.
  12. Pereira M, et al. Acute kidney injury in patients with severe sepsis or septic shock: a comparison between the RIFLE, AKIN and KDIGO classifications. Clin Kidney J. 2017 Jun;10(3):332–40.
  13. National Kidney Foundation. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis. 2002 Feb;39(2 Suppl 1):S1–266.
  14. Webster AC, Nagler EV, Morton RL, Masson P. Chronic kidney disease. Lancet. 2017 Mar 25;389(10075):1238–52.
  15. Eckardt KU, Coresh J, Devuyst O, Johnson RJ, Köttgen A, Levey AS, et al. Definition and classification of CKD: the debate should be about patient prognosis—A position statement from KDOQI and KDIGO. Am J Kidney Dis. 2009 Jun;53(6):915–20.
  16. Eknoyan G. Chronic kidney disease definition and classification: the quest for refinements. Kidney Int. 2007 Nov;72(10):1183–5.
  17. Anders HJ, Andersen K, Stecher B. The intestinal microbiota, a leaky gut, and abnormal immunity in kidney disease. Kidney Int. 2013 Jun;83(6):1010–6.
  18. Vanholder R, Baurmeister U, Brunet P, Cohen G, Glorieux G, Jankowski J, et al. A bench to bedside view of uremic toxins. J Am Soc Nephrol. 2008 May;19(5):863–70.
  19. Webster AC, Nagler EV, Morton RL, Masson P. Chronic Kidney Disease. Lancet. 2017 Mar 25;389(10075):1238–52.
  20. Perico N, Sheppati A, Remuzzi G. Scientific care for prevention: an overview. Kidney Int Suppl. 2005 Mar;67(94):S136–41.
  21. Sanjay AK. Chronic kidney disease and its prevention. Kidney Int Suppl. 2005 Feb;68(98):S41–5.
  22. Wavamunno MD, Harris DCH. The need for early nephrology referral. Kidney Int Suppl. 2005 Mar;67(94):128–32.
  23. United States Renal Data System. 2018 USRDS Annual Data Report: Epidemiology of Kidney Disease in the United States. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2018.
  24. Kidney Disease: Improving Global Outcomes (KDIGO) Lipid Work Group. KDIGO clinical practice guideline for lipid management in chronic kidney disease. Kidney Int Suppl. 2013 Jul;3(3):259–305.
  25. Tonelli M, Wanner C; KDIGO Lipid Guideline Development Work Group Members. Lipid management in chronic kidney disease: synopsis of the KDIGO 2013 clinical practice guideline. Ann Intern Med. 2014 Feb 4;160(3):182. doi:10.7326/M13-2455.
Regular Issue Open Access Review Article
Volume 15
Issue 02
Received 25/03/2025
Accepted 08/08/2025
Published 27/08/2025
Publication Time 155 Days
141

Login


My IP

PlumX Metrics